cyclodextrin technologies development, inc. (ctd), the "company", was organized as a florida corporation on august 9, 1990 with operations beginning july, 1992. in may of 1994 the company became a fully reporting public company listed on the otc bb under the symbol ctdi. in 2000, the company altered its corporate structure to a holding company with subsidiary companies. the otc bb symbol was changed to ctdh. ctd holdings, inc. (the "company") was originally formed to market and sell cyclodextrins and related products to the food, pharmaceutical, and other industries; it also provided consulting services related to cyclodextrin technology. ctdh, as a holding company, will acquire, create, and invest in companies that will develop, market, and/or sell products containing cyclodextrins. the company currently operates four wholly owned subsidiaries: ctd, inc.; nanosonic products, inc.; sphingo biotech, inc.; and ferrazo environmental technologies, inc.
Company profile
Ticker
CYTH
Exchange
Website
CEO
Nathan Scott Fine
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CTD HOLDINGS INC, CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC
SEC CIK
Corporate docs
Subsidiaries
Cyclodextrin Technologies Development, Inc. • Cameo Merger Sub, Inc. ...
IRS number
593029743
CYTH stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
18 Mar 24
8-K/A
Financial Statements and Exhibits
4 Mar 24
8-K
Other Events
22 Jan 24
8-K
Material Modifications to Rights of Security Holders
28 Dec 23
8-K
Completion of Acquisition or Disposition of Assets
27 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
26 Dec 23
425
Business combination disclosure
18 Dec 23
8-K
Other Events
18 Dec 23
425
Business combination disclosure
30 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.80 mm | 1.80 mm | 1.80 mm | 1.80 mm | 1.80 mm | 1.80 mm |
Cash burn (monthly) | (no burn) | 207.33 k | 1.59 mm | 1.62 mm | 1.35 mm | 1.22 mm |
Cash used (since last report) | n/a | 1.38 mm | 10.58 mm | 10.75 mm | 8.96 mm | 8.11 mm |
Cash remaining | n/a | 422.75 k | -8.78 mm | -8.95 mm | -7.16 mm | -6.31 mm |
Runway (months of cash) | n/a | 2.0 | -5.5 | -5.5 | -5.3 | -5.2 |
Institutional ownership, Q2 2023
11.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 16 |
Opened positions | 3 |
Closed positions | 4 |
Increased positions | 4 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 703.41 mm |
Total shares | 3.18 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
RFL Rafael Holdings Inc - Ordinary Shares | 2.51 mm | $3.47 mm |
Vanguard | 260.38 k | $414.00 mm |
Hirschman Orin | 209.38 k | $2.79 mm |
Geode Capital Management | 100.39 k | $159.62 mm |
STT State Street | 28.30 k | $45.00 mm |
Renaissance Technologies | 17.80 k | $28.00 k |
Citadel Advisors | 16.98 k | $27.00 mm |
NTRS Northern Trust | 16.59 k | $26.38 mm |
Tower Research Capital | 7.14 k | $11.35 mm |
Advisor | 4.60 k | $7.31 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Feb 24 | William Conkling | Common Stock | Grant | Acquire A | No | No | 0 | 6,330 | 0.00 | 16,245 |
13 Feb 24 | Sieger Markus | Common Stock | Grant | Acquire A | No | No | 0 | 14,004 | 0.00 | 310,679 |
13 Feb 24 | Ostronic Francis Patrick | Common Stock | Grant | Acquire A | No | No | 0 | 8,703 | 0.00 | 338,028 |
13 Feb 24 | Toig Randall M. | Common Stock | Grant | Acquire A | No | No | 0 | 7,516 | 0.00 | 104,891 |
13 Feb 24 | Strattan Ce Rick | Common Stock | Grant | Acquire A | No | No | 0 | 6,963 | 0.00 | 286,596 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
18 Apr 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
2 Apr 24
Cyclo Therapeutics Receives Decision To Grant European Patent Titled 'METHODS FOR TREATING ALZHEIMER'S DISEASE WITH HP-[BETA]-CYCLODEXTRIN'
2 Apr 24
Cyclo Therapeutics Announces Issuance Of U.S. Patent Covering The Use Of Trappsol Cyclo For The Treatment Of Alzheimer's Disease
14 Mar 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
13 Mar 24